Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997;350:1047-1059. Abstract

Casper RF. Estrogen with interrupted progestin HRT: a review of experimental and clinical studies. Maturitas 2000;34:97-108. Abstract

Chlebowski RT, McTiernan A. Elements of informed consent for hormone replacement therapy in patients with diagnosed breast cancer. J Clin Oncol 1999;17(1):130-42. Abstract

Cobleigh MA et al. Hormone replacement therapy and high S phase in breast cancer. JAMA 1999;281:1528-30. Abstract

Col NF et al. Hormone replacement therapy after breast cancer: A systematic review and quantitative assessment of risk. J Clin Oncol 2001;19(8):2357-63. Abstract

Colditz GA. Estrogen replacement therapy for breast cancer patients.
Oncology (Huntingt) 1997;11(10):1491-4, 1497; discussion 1498, 1501. Abstract

Ettinger B et al. Cyclic hormone replacement therapy using quarterly progestin. Obstet Gynecol. 1994;83(5 Pt 1):693-700. Abstract

Fisher B et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90(18):1371-88. Abstract

Ganz PA. Menopause and breast cancer: symptoms, late effects, and their management. Semin Oncol 2001;28(3):274-83. Abstract

Greendale GA et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Ann Intern Med 1999;130(4 Pt 1):262-9. Abstract

Hofseth LJ et al. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 1999;84(12):4559-65. Abstract

Jacobs HS. Hormone replacement therapy and breast cancer. Endocr Relat Cancer 2000;7(1):53-61. Full-Text

Lundstrom E et al. Mammographic breast density during hormone replacement therapy: effects of continuous combination, unopposed transdermal and low-potency estrogen regimens. Climacteric 2001;4(1):42-8. Abstract

Magnusson C et al. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer 1999;81(3):339-44. Abstract

Manjer J et al. Increased incidence of small and well-differentiated breast tumours in post-menopausal women following hormone-replacement therapy. Int J Cancer 2001;92:919-22. Abstract

Marsden J et al. Are randomized trials of hormone replacement therapy in symptomatic women with breast cancer feasible? Fertil Steril 2000;73(2):292-9. Abstract

McCarty MF. Androgenic progestins amplify the breast cancer risk associated with hormone replacement therapy by boosting IGF-I activity. Med Hypotheses 2001;56(2):213-6. Abstract

O'Meara ES et al. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 2001;93(10):754-62. Abstract

Ozdemir A et al. Mammographic and ultrasonographic study of changes in the breast related to HRT. Int J Gynaecol Obstet 1999;67:23-32. Abstract

Pike MC, Ross RK. Progestins and menopause: epidemiological studies of risks of endometrial and breast cancer. Steroids 2000;65(10-11):659-64. Abstract

Pritchard KI. Hormone replacement in women with a history of breast cancer.
Oncologist 2001;6(4):353-62. Abstract

Raafat AM et al. Estrogen and estrogen plus progestin act directly on the mammary gland to increase proliferation in a postmenopausal mouse model. J Cell Physiol 2001;187(1):81-9. Abstract

Ross RK et al. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92(4):328-32. Abstract

Rutter CM et al. Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy. JAMA 2001;285:171-6. Abstract

Salmon RJ et al. Clinical and biological characteristics of breast cancers in post-menopausal women receiving hormone replacement therapy for menopause. Oncol Rep 1999;6:699-703. Abstract

Schairer C et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000;283(4):485-91. Abstract

Sterns EE, Zee B. Mammographic density changes in perimenopausal and postmenopausal women: is effect of hormone replacement therapy predictable? Breast Cancer Res Treat 2000;59(2):125-32. Abstract

Williams DB et al. Assessment of less than monthly progestin therapy in postmenopausal women given estrogen replacement. Obstet Gynecol. 1994;84(5):787-93. Abstract

Home · Search